Companies
Employees51-200
Funding$1B
Valuation$2.85B
23 active roles
OtherPublic$1B+
About
Kailera Therapeutics is a late clinical-stage biotechnology company developing a diversified pipeline of GLP-1-based therapies for the treatment of obesity and related conditions. They develop both injectable and oral formulations, featuring a lead candidate ribupatide, to address unmet needs in weight management. The company aims to provide category-leading medications through a combination of proprietary clinical development and strategic licensing.
Active Roles
23Key Investors
Bain Capital Private Equity, CPP Investments, Qatar Investment Authority, Adage Capital Management LP, Invus, Janus Henderson Investors, Perseverance Capital, Royalty Pharma, Surveyor Capital, Atlas Venture, Bain Capital Life Sciences, RTW Investments, Sirona Capital